中国医药
中國醫藥
중국의약
China Medicine
2015年
10期
1452-1455
,共4页
脑梗死%羟苯磺酸钙%C反应蛋白%神经肽Y%皮质醇
腦梗死%羥苯磺痠鈣%C反應蛋白%神經肽Y%皮質醇
뇌경사%간분광산개%C반응단백%신경태Y%피질순
Cerebral infarction%Calcium dobesilate%C reactive protein%Neuropeptide Y%Cortisol
目的 探讨羟苯磺酸钙对脑梗死患者C反应蛋白(CRP)、神经肽Y和皮质醇水平的影响.方法 选取2011年1月至2014年11月山东省淄博市中西医结合医院收治的80例脑梗死患者作为研究对象,所有患者按照随机数字表法分为观察组和对照组,各40例.对照组患者采用常规治疗,观察组患者在常规治疗的基础上加用羟苯磺酸钙(500 mg/次,3次/d口服),持续治疗2周.比较2组患者病情严重程度,观察美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数、CRP、神经肽Y和皮质醇水平的变化.结果 观察组与对照组患者的脑梗死体积差异无统计学意义[(7±4)cm3比(7±4)cm3,P＞0.05].观察组大梗死灶11例、中梗死灶17例、小梗死灶12例;对照组大梗死灶10例、中梗死灶18例、小梗死灶12例,差异无统计学意义(Z=1.423,P＞0.05).治疗前,观察组与对照组患者的NIHSS评分、Barthel指数差异无统计学意义(P＞0.05).治疗2周后,观察组NIHSS评分明显低于治疗前和对照组、Baahel指数明显高于治疗前和对照组,差异均有统计学意义[(11.4±3.2)分比(19.6±5.1)、(15.1±2.7)分,(74±12)分比(48±18)、(62±7)分,均P＜0.05];治疗前,观察组与对照组患者的CRP、神经肽Y、皮质醇差异无统计学意义[(4.1 ±0.6)mg/L比(4.1 ±0.7) mg/L、(270 42) ng/L比(272±42) ng/L、(421±45) μg/L比(420±45) μg/L] (P ＞0.05).治疗1周和2周后,观察组患者的CRP、神经肽Y、皮质醇水平明显低于对照组,差异均有统计学意义[治疗1周后:(4.7±0.4) mg/L比(5.5 ±0.5) mg/L、(309±45) ng/L比(357±40) ng/L、(216 ±57) μg/L比(298±42) μg/L;治疗2周后:(3.2±0.5) mg/L比(3.7±0.3) mg/L、(98±38) ng/L比(122±40) ng/L、(174±32) μg/L比(213±27) μg/L](均P＜0.05);且2组患者治疗2周后CRP、神经肽Y和皮质醇水平均明显低于治疗前,差异均有统计学意义(均P＜0.05).结论 羟苯磺酸钙可以明显改善脑梗死患者的NIHSS评分和Baahel指数,降低患者的CRP、神经肽Y和皮质醇水平.
目的 探討羥苯磺痠鈣對腦梗死患者C反應蛋白(CRP)、神經肽Y和皮質醇水平的影響.方法 選取2011年1月至2014年11月山東省淄博市中西醫結閤醫院收治的80例腦梗死患者作為研究對象,所有患者按照隨機數字錶法分為觀察組和對照組,各40例.對照組患者採用常規治療,觀察組患者在常規治療的基礎上加用羥苯磺痠鈣(500 mg/次,3次/d口服),持續治療2週.比較2組患者病情嚴重程度,觀察美國國立衛生研究院卒中量錶(NIHSS)評分、Barthel指數、CRP、神經肽Y和皮質醇水平的變化.結果 觀察組與對照組患者的腦梗死體積差異無統計學意義[(7±4)cm3比(7±4)cm3,P＞0.05].觀察組大梗死竈11例、中梗死竈17例、小梗死竈12例;對照組大梗死竈10例、中梗死竈18例、小梗死竈12例,差異無統計學意義(Z=1.423,P＞0.05).治療前,觀察組與對照組患者的NIHSS評分、Barthel指數差異無統計學意義(P＞0.05).治療2週後,觀察組NIHSS評分明顯低于治療前和對照組、Baahel指數明顯高于治療前和對照組,差異均有統計學意義[(11.4±3.2)分比(19.6±5.1)、(15.1±2.7)分,(74±12)分比(48±18)、(62±7)分,均P＜0.05];治療前,觀察組與對照組患者的CRP、神經肽Y、皮質醇差異無統計學意義[(4.1 ±0.6)mg/L比(4.1 ±0.7) mg/L、(270 42) ng/L比(272±42) ng/L、(421±45) μg/L比(420±45) μg/L] (P ＞0.05).治療1週和2週後,觀察組患者的CRP、神經肽Y、皮質醇水平明顯低于對照組,差異均有統計學意義[治療1週後:(4.7±0.4) mg/L比(5.5 ±0.5) mg/L、(309±45) ng/L比(357±40) ng/L、(216 ±57) μg/L比(298±42) μg/L;治療2週後:(3.2±0.5) mg/L比(3.7±0.3) mg/L、(98±38) ng/L比(122±40) ng/L、(174±32) μg/L比(213±27) μg/L](均P＜0.05);且2組患者治療2週後CRP、神經肽Y和皮質醇水平均明顯低于治療前,差異均有統計學意義(均P＜0.05).結論 羥苯磺痠鈣可以明顯改善腦梗死患者的NIHSS評分和Baahel指數,降低患者的CRP、神經肽Y和皮質醇水平.
목적 탐토간분광산개대뇌경사환자C반응단백(CRP)、신경태Y화피질순수평적영향.방법 선취2011년1월지2014년11월산동성치박시중서의결합의원수치적80례뇌경사환자작위연구대상,소유환자안조수궤수자표법분위관찰조화대조조,각40례.대조조환자채용상규치료,관찰조환자재상규치료적기출상가용간분광산개(500 mg/차,3차/d구복),지속치료2주.비교2조환자병정엄중정도,관찰미국국립위생연구원졸중량표(NIHSS)평분、Barthel지수、CRP、신경태Y화피질순수평적변화.결과 관찰조여대조조환자적뇌경사체적차이무통계학의의[(7±4)cm3비(7±4)cm3,P＞0.05].관찰조대경사조11례、중경사조17례、소경사조12례;대조조대경사조10례、중경사조18례、소경사조12례,차이무통계학의의(Z=1.423,P＞0.05).치료전,관찰조여대조조환자적NIHSS평분、Barthel지수차이무통계학의의(P＞0.05).치료2주후,관찰조NIHSS평분명현저우치료전화대조조、Baahel지수명현고우치료전화대조조,차이균유통계학의의[(11.4±3.2)분비(19.6±5.1)、(15.1±2.7)분,(74±12)분비(48±18)、(62±7)분,균P＜0.05];치료전,관찰조여대조조환자적CRP、신경태Y、피질순차이무통계학의의[(4.1 ±0.6)mg/L비(4.1 ±0.7) mg/L、(270 42) ng/L비(272±42) ng/L、(421±45) μg/L비(420±45) μg/L] (P ＞0.05).치료1주화2주후,관찰조환자적CRP、신경태Y、피질순수평명현저우대조조,차이균유통계학의의[치료1주후:(4.7±0.4) mg/L비(5.5 ±0.5) mg/L、(309±45) ng/L비(357±40) ng/L、(216 ±57) μg/L비(298±42) μg/L;치료2주후:(3.2±0.5) mg/L비(3.7±0.3) mg/L、(98±38) ng/L비(122±40) ng/L、(174±32) μg/L비(213±27) μg/L](균P＜0.05);차2조환자치료2주후CRP、신경태Y화피질순수평균명현저우치료전,차이균유통계학의의(균P＜0.05).결론 간분광산개가이명현개선뇌경사환자적NIHSS평분화Baahel지수,강저환자적CRP、신경태Y화피질순수평.
Objective To explore the effect of calcium dobesilate on C reactive protein (CRP),neuropeptide Y (NPY) and cortisol in patients with cerebral infarction (CI).Methods Totally 80 patients with CI from Junuary 2011 to November 2014 were enrolled and randomly divided into control group (40 cases) receiving conventional therapy and observation group (40 cases) receiving conventional therapy ± calcium dobesilate (500 mg/time,3 times/d,oral).The treatment lasted for 2 weeks.The changes of disease severity,national institute of health stroke scale (NIHSS),barthel index (BI),CRP,NPY and cortisol were compared between the two gruops.Results The infarction volume was not significantly different between observation group and control group[(7 ±4) cm3 vs (7 ±4) cm3,P ＞0.05].There were 11 eases of severe infarction,17 cases of moderate infarction and 12 cases of mild infarction in observation group;there were 10 cases of severe infarction,18 cases of moderate infarction and 12 cases of mild infarction in control group;no significant differences were found between the two groups (Z =1.423,P ＞ 0.05).Before treatment,NIHSS and BI in observation group were both not significantly different compared with those in control group (P ＞ 0.05);after 2 weeks of treatment,NIHSS was significant lower than pretreatment and control group and BI was significant higher than pretreatment and control group [(11.4±3.2) scores vs (19.6±5.1),(15.1 ±2.7) scores,(74±12) scores vs (48±18),(62± 7) scores] (P ＜ 0.05).Before treatment,CRP,NPY and cortisol were all not significantly different between observation group and control group [(4.1 ±0.6) mg/L vs (4.1 ±0.7) mg/L,(270 ±42) ng/L vs (272 ±42) ng/L,(421 ± 45) μg/L vs (420 ± 45) μμg/L] (P ＞ 0.05);after 1 and 2 weeks of treatment,above indices were significantly lower in observation group compared with those in control group [1 week:(4.7 ±0.4) mg/L vs (5.5 ±0.5) mg/L,(309±45) ng/L vs (357 ±40) ng/L,(216 ±57) μg/L vs (298 ±42) μg/L;2 weeks:(3.2 ±0.5) mg/L vs (3.7 ±0.3) mg/L,(98 ± 38) ng/L vs (122 ±40) ng/L,(174 ± 32) μg/L vs (213 ±27) μg/L];after 2 weeks of treatment,above indices were all significantly tower than pretreatment in both groups (P ＜ 0.05).Conclusion Calcium dobesilate can effectively ameliorate the NIHSS and BI in patients with cerebral infarction;it can decrease the CRP,NYP and cortisol levels.
